Speeches by Moran.

“Build E1, kill the prospect of Palestine. It is that simple, and that is not a conspiracy theory; it is Israel’s stated aim. We have a small window to affect what happens next because the Israeli elections are happening soon, as the Minister said. If we are going to make any difference to the ordinary Israeli politic a…”

“I am happy not to. Question deferred (Standing Order No. 54).”

“I am frustrated, because everything the Minister is saying is in the press release. Can she please answer the question? Will the Government release the impact assessment? If they will not, will they at least allow a Select Committee to see it confidentially?”

“I believe that by the end of my speech, the hon. Gentleman and I will be in violent agreement, if we are not already. There is one more aspect of this, incidentally: the supply chains deal, which I understand is being crafted. We do not have time to go into that.”

“The hon. Gentleman is absolutely right, and that lack of transparency is the nub of my speech today. There are some potential positives in the deal. At the 10 February sitting of the Business and Trade Committee, a representative of the Association of the British Pharmaceutical Industry said that zero tariffs and commi…”

“I thank the Backbench Business Committee for granting this debate on the NHS estimates and, in particular, the impact of the UK-US pharmaceutical deal. Let me start by briefly talking about the estimates themselves. I am sure that every Member has a copy of them; I have one every year. Given that we spend £211 billion …”

“I, too, thank Baroness Amos, her team and, most especially, the families who so bravely gave the evidence that has formed this report. Further to the conversation about accountability, the Secretary of State will have noticed that some families are concerned that the commissioner is just one person, and that there is t…”

“I am grateful to the hon. Gentleman for his speech, because he is showing how important this debate is. A lot of this has not been flushed out. Medicines UK, which is responsible for a lot of the generics that he talks about, disagrees with him, but that is a conversation for another time. My question is specific: does…”

“That is a really good point. I will come back to generics, which make up nine in 10 of the medicines that the NHS uses. There is also an issue of devolution here, which I am sure other Members will cover. At the moment it is very complex, and it is not at all clear how the deal will apply in Scotland and Northern Irela…”

“I, too, pay tribute to those families who came forward with their stories, but also to the thousands, if not tens of thousands, of families across the country who are hearing these stories today and are triggered because it reminds them of their own, including in my area in Oxfordshire. What struck me most about the re…”

“I welcome the statement and this approach. I thank the MHRA for engaging with the Committee when we asked it specific questions about this. It told us that the role of the regulator is to ensure that participants in any clinical trial are kept safe and are exposed to medicine only if there is a reasonable expectation o…”

“That did not exist, but currently funding is flowing through the ICBs?”

“The practitioner will have, as you say, a manual in front of them leading them through the activities?”

“This is what I am trying to get to. We have a lot of turmoil going on in this space currently. I appreciate your research is long standing and this is much more recent, but are you getting a sense of any impact on these teams as a result of the turmoil?”

“That is helpful for us to pursue. Are the teams that are trying to meet all needs effectively going to have to wait until someone leaves and then replace them with someone with different skills? Is that how they are managing that, or are they just not providing the right services?”

“Is it dangerous? Would you go so far as to say that?”

“I will come back to the roll-out—the ideal of the full coverage by 2029-30. Out of 10, what are the chances that we will get to 100% coverage of every school by 2029-30 if we keep going at the current rate?”

“Yes, what does that mean?”

“The key point is that when we talk about integration with early support hubs and so on, they just do not get mentioned. That is interesting in itself. Perhaps unsurprisingly, I went to visit one in Devon and the vast majority of young people there were there because they felt, in their words, that school had failed the…”

“That was presumably flowed through the ICBs?”